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The Eﬀectiveness and Cost-Eﬀectiveness of
Spinal Cord Stimulation for Refractory Angina
(RASCAL Study): A Pilot Randomized
Controlled Trial
Sam Eldabe, MD*; Simon Thomson, MD†; Rui Duarte, PhD‡; Morag Brookes,
RGN, MSc*; Mark deBelder, MD§; Jon Raphael, MD¶; Ed Davies, MD**;
Rod Taylor, PhD††
Background: Patientswith“refractory angina”(RA) unsuitable for coronary revascularization experience high levels of hospitaliza-
tion andpoor health-related quality of life. Randomized trials have shown spinal cord stimulation (SCS) to be a promising treatment
for chronic stable angina and RA; however, none has compared SCS with usual care (UC). The aim of this pilot study was to address
the key uncertainties of conducting a deﬁnitive multicenter trial to assess the clinical and cost-eﬀectiveness of SCS in RA patients,
i.e., recruitment and retention of patients, burden of outcomemeasures, our ability to standardize UC in a UK NHS setting.
Methods: RA patients deemed suitable were randomized in a 1:1 ratio to SCS plus UC (SCS group) or UC alone (UC group). We
sought to assess: recruitment, uptake, and retention of patients; feasibility and acceptability of SCS treatment; the feasibility and
acceptability of standardizing UC; and the feasibility and acceptability of the proposed trial outcome measures. Patient outcomes
were assessed at baseline (prerandomization) and three and six months postrandomization.
Results: We failed tomeet our planned recruitment target (45 patients) and randomized 29 patients (15 SCS group, 14 UC group) over a
42-monthperiodacross foursites.Noneofthestudyparticipantschosetowithdrawfollowingconsentandrandomization.Withexceptionof
twodeaths,allcompletedevaluationatbaselineandfollow-up.Althoughthestudywasnotformallypoweredtocompareoutcomesbetween
groups,we sawa trend toward larger improvements in bothprimary and secondary outcomes in the SCSgroup.
Conclusions: While patient recruitment was found to be challenging, levels of participant retention, outcome completion, and
acceptability of SCS therapy were high. A number of lessons are presented in order to take forward a future deﬁnitive pragmatic
randomized trial.
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Conﬂict of Interest: The authors wish to disclose the following competing interests: Sam Eldabe and Rod Taylor have received
consultancy fees from Medtronic. Rod Taylor is currently an independent member of Trial Steering Committees for PROCESS and
SubQStim, two ongoing Medtronic-funded studies. Simon Thomson has received consultancy fees from Boston Scientiﬁc. The
other authors have no conﬂicts of interest.
Address correspondence to: Sam Eldabe, FFPMRCA, Department of Pain and Anaesthesia, The James Cook University Hospital, Cheriton House, Marton Road, Middles-
brough TS4 3BW, UK. Email: seldabe@mac.com
* Department of Pain and Anesthesia, The James Cook University Hospital, Middlesbrough, UK;
† Basildon and Thurrock University Hospitals, Basildon, Nethermayne, UK;
‡ School of Health and Population Sciences, University of Birmingham, Birmingham, UK;
§ Department of Cardiology, The James Cook University Hospital, Middlesbrough, UK;
¶ Department of Pain Medicine, Dudley Group of Hospitals NHS Foundation Trust, Russells Hall Hospital, Dudley, West Midlands, UK;
** Cardiothoracic Department, Plymouth Hospitals NHS Trust, Plymouth, UK; and
†† University of Exeter Medical School, University of Exeter, Exeter, UK
For more information on author guidelines, an explanation of our peer review process, and conﬂict of interest informed consent policies, please go to
http://www.wiley.com/WileyCDA/Section/id-301854.html
Funding sources: This article presents independent research funded by the National Institute of Health Research (NIHR) under its Research for Patient Beneﬁt (RfPB)
program (grant reference: PB-PG-1208-18031). Rod Taylor is supported by the NIHR Collaboration for Leadership in Applied Health Research and Care South West
Peninsula (PenCLARHC) at the Royal Devon and Exeter NHS Foundation Trust. The views expressed here are those of the authors and not necessarily those of the NHS,
the NIHR or the Department of Health. The NIHR had no role in study design, writing of the manuscript or the decision to submit for publication.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in anymedium,
provided the original work is properly cited, the use is non-commercial and no modiﬁcations or adaptations are made.
Neuromodulation: Technology at the Neural Interface
Received: June 23, 2015 Revised: August 8, 2015 Accepted: August 10, 2015
(onlinelibrary.wiley.com) DOI: 10.1111/ner.12349
1
www.neuromodulationjournal.com Neuromodulation 2015; ••: ••–••© 2015 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society.
INTRODUCTION
Refractory angina (RA) has been deﬁned as “a chronic condition
characterized by the presence of angina caused by coronary insuf-
ﬁciency in the presence of coronary artery disease which cannot be
controlled by a combination of medical therapy, angioplasty and
coronary bypass surgery. The presence of reversible myocardial
ischaemia should be clinically established to be the cause of the
symptoms. Chronic is deﬁned as a duration of more than 3 months”
(1). The commonest causes of unsuitability for revascularization are
unfavorable coronary anatomy, unsuccessful response to receiving
one or more previous coronary bypass procedures or percutaneous
angioplasties, lack of suitable grafting material, signiﬁcant extra
cardiac comorbidities, or advanced age, often in combination of the
above (1–4). Both increasing success and innovation in conven-
tional approaches to treat angina and better survival rates following
primary and subsequent coronary events have led to signiﬁcant
proportions of patients presenting with angina refractory to con-
ventional treatment (4). The most recent published estimate of the
incidence of RA is 25,000 to 75,000 new cases per year and an
estimated prevalence of 300,000 to 900,000 patients in the United
States (5). The wide variability in prevalence and incidence ﬁgures
may be due to a lack of a standardized deﬁnition, as the diagnosis of
refractory angina depends on the lack of revascularization alterna-
tives, which vary in diﬀerent contexts according to the availability of
revascularization technology, appropriateness of medical treat-
ment, and other interventions targeted to control anginal pain (6).
RA patients experience severe chest pain leading to a high rate of
hospitalization, resource use, and poor levels of health-related
quality of life (HRQoL) (1,7).
RA patients can be oﬀered a number of therapies including anti-
angina drugs, sympathectomy, analgesics, angina management
cognitive behavioral therapy, stimulation-induced analgesia, stel-
late ganglion block, epidural blocks, spinal cord stimulation (SCS),
enhanced external counterpulsation, and percutaneous laser myo-
cardial revascularization (3,8–10).
It has been suggested that SCS produces its eﬀects in refractory
angina via an interaction of the following mechanisms: 1) pain
reduction; 2) a reduction of sympathetic tone; 3) reduced myocar-
dial oxygen demand; and 4) improved coronary microcirculatory
blood ﬂow, resulting in a lessening of myocardial ischemia (11).
Attenuation of pain is accomplished by stimulation of the dorsal
columns and an accompanying decrease in the transmission of
nociceptive impulses via the spinothalamic tract. This may occur via
an increase in γ-amino butyric acid (GABA) release from dorsal horn
interneurons and also by release of beta-endorphins, which is asso-
ciated with decreased myocardial oxygen consumption. Human
studies of norepinephrine spillover as well as other animal models
have shown a clear eﬀect of SCS on the sympathetic system with
consequent reduction in oxygen demand (12–14). Further improve-
ment of myocardial ischemia occurs due to improved blood ﬂow at
the coronary microvascular level, which is supported by studies
showing increased homogenization of myocardial blood ﬂow
(15,16). Animal models have shown that SCS modiﬁes the capacity
of intrinsic cardiac neurons to generate activity (17). SCS also acts to
suppress the excitatory eﬀects that local myocardial ischemia exerts
on such neurons.
Two systematic reviews and meta-analyses have indicated that
SCS can improve anginal symptoms, functional status, and HRQoL
of individuals with RA with no negative eﬀects on mortality (18,19).
However, trials to date have been small, range considerably in
their methodological quality, and have included variable and
nonpragmatic comparators. In 2008, the National Institute for
Health and Care Excellence (NICE) in the United Kingdom concluded
that there was inadequate evidence to recommend the routine use
of SCS and called for a pragmatic randomized controlled trial (RCT)
that compares SCS against current usual care management for RA
(20,21).
The overarching aim of this pilot study was to assess the feasibil-
ity of undertaking a deﬁnitive multicenter trial to assess the clinical
eﬀectiveness and cost-eﬀectiveness of adding SCS to usual care in
patients with RA. Before undertaking such a deﬁnitive study, a
number of uncertainties exist. The speciﬁc objectives of this study
were to address these key uncertainties: 1) assess recruitment,
uptake, and retention of patients; 2) assess the feasibility and
acceptability of SCS treatment from the point of view of patients
and referring physicians; 3) assess the feasibility and acceptability of
standardizing usual care; and 4) test the feasibility and acceptability
of the proposed trial outcome measures in both groups.
METHODS
The study design and methods have been described in the pub-
lished study protocol (22) and are summarized here.
Study Design
The Refractory Angina Spinal Cord stimulation and usuAL care
study (RASCAL) study is a pragmatic multicenter external pilot RCT
that allocated RA patients to receive SCS plus usual care (“SCS
group”) or usual care alone (“UC group”). Recruitment took place in
four English centers (The James Cook University Hospital, South
Tees Hospitals NHS Foundation Trust; Russells Hall Hospital, Dudley
Group of Hospitals NHS Foundation Trust; Basildon University Hos-
pital, Basildon and Thurrock University Hospitals NHS Foundation
Trust; and Derriford Hospital, Plymouth Hospitals NHS Trust)
between January 2011 and June 2014.
Given the paresthesia associated with SCS, it was not possible to
blind patients, clinicians, or researchers to group allocation.
However, given the potential observer bias associated with assess-
ing exercise capacity, we sought to blind those conducting this
outcome assessment. The research nurses conducting the remain-
der of the data collection were independent of the delivery of
patient care in the trial.
The study was reviewed by the Ethics committee NRES commit-
tee UK North East Northern and Yorkshire and received a favorable
opinion in July 2011 reference: 11/NE/0175. The study was regis-
tered with ISRCTN65254102. All patients provided written informed
consent prior to randomization.
Study Population
Patients were eligible for inclusion if they were 18 years of age or
olderwith limitinganginadespiteoptimal anti-angina therapy, hada
Canadian Cardiovascular Society functional classiﬁcation of angina
of Class III or IV, and had angiographically documented Ccoronary
artery disease that was deemed not suitable for revascularization by
the referring cardiologist or cardiothoracic surgeon. In addition, all
eligible patients had to show demonstrable ischemia on functional
testing and satisfactory multidisciplinary assessment in accordance
with the British Pain Society guidelines for SCS (23).
Exclusions includedapacemakeror implanteddeﬁbrillator incom-
patiblewith SCS, a comorbidity consideredby the assessing clinician
2
ELDABE ET AL.
www.neuromodulationjournal.com Neuromodulation 2015; ••: ••–••© 2015 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society
to overshadow the eﬀect of the angina or render a patient an unsuit-
able candidate forneuromodulation (e.g., advancedspinaldiseaseor
deformity), poor cognitive ability, ongoing anticoagulation therapy
(where anticoagulants cannot be safely discontinued without jeop-
ardizing patient safety), or refusal to participate in the study.
Patients fulﬁlling these criteria were consented and oﬀered entry
to the study.
Study Procedure
Eligible patients were randomized sequentially to either the SCS
or the UC group in a 1:1 ratio. The randomization sequence was
computer generated and stratiﬁed by hospital, age, gender, and
Canadian Cardiovascular Society functional classiﬁcation of angina.
The randomization sequence was prepared by the trial statistician
(RT) and allocation concealment maintained by only revealing
allocation of each participant by email correspondence to the
study coordinator following completion of baseline outcomes.
Interventions
SCS
For the patients allocated to the SCS group, the intervention was
started within six weeks from the date of randomization with an
acute on-table trial of SCS followed by full implantation if the trial
was successful. In case of failure to obtain >80% paresthesia cover-
age of the painful area or if painful sensations were generated when
the temporary stimulator was switched on, the procedure was
aborted and the leads removed with no full implantation (“failed
trial”). Participants who had a failed trial of SCS continued to receive
treatment and follow-up as per the study protocol (both groups
were to receive UC).
The SCS implant was performed by an experienced health pro-
fessional (i.e., ≥15 SCS implants in the previous 12 months) at the
Pain Departments across the four study sites. The procedure con-
sisted of inserting one or two epidural leads of SCS through a
needle into a thoracic epidural interspace under local anesthetic
with patients either in prone, lateral, or sitting position according
to patient and operator preference. The leads were positioned at
C7/T1 (N = 7), T11/T12 (N = 1), T1/T2 (N = 5), and C2 (N = 1). Once
in position, the leads were connected to an external stimulator
and the position adjusted to obtain optimum coverage of the
painful area. In cases where the paresthesia covered 80% or more
of the painful area, the leads were anchored to the spine via a
small incision and connected via tunneled subcutaneous exten-
sions, where required, to an implanted pulse generator placed in
the anterior abdominal wall or the buttock. Implanted participants
were instructed on how to adjust their SCS device to generate a
comfortable paresthesia level. They were instructed to do this
regularly for two hours, three times per day to terminate any
angina attack for as long as is necessary or before any exertion
known or anticipated to generate angina pain.
UC
In order to standardize the delivery of UC, it was agreed by the site
investigators that both groups of participants across the four
Figure 1. RASCAL study CONSORT diagram.
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research sites be oﬀered the following sequence of UC therapies: an
education session with a pain consultant; trial of a transcutaneous
electrical nerve stimulation (TENS); serial thoracic sympathectomy
(where no medical contraindications existed); and oral or systemic
analgesics and adjuvant analgesia. UC was based on a survey of
current RA management in the UK reported in the study protocol
(22). It should be noted that thoracic sympathectomy, although
common practice in the UK, may not be routinely used in other
countries and is not recommended in the European Society of Car-
diology (24) and American College of Cardiology/American Heart
Association guidelines (25). These therapieswere started, if possible,
on the day of randomization and were received sequentially where
this was felt to be clinically appropriate by the investigator. Partici-
pants who had already tried and failed to obtain relief from any of
the sequence of therapies above, were moved onto the next
therapy. Following completion of the above sequence, the treating
physician was able to apply any therapy deemed appropriate, with
the exception of repeat coronary artery bypass graft, percutaneous
revascularization (or stenting), percutaneous myocardial laser
revascularization, or enhanced external counterpulsation. Any
patient with a signiﬁcant and sudden downturn in their symptoms
could be reevaluated by their cardiologists, including repeat angi-
ography and a reappraisal of revascularization options if the
angiographic ﬁndings had changed. Given the pragmatic nature of
this pilot trial, we did not seek to control the pattern of accepted UC
Table 1. Baseline Demographic Characteristics.
UC group, N = 14 SCS group, N = 15
N (%) or mean (SD) N (%) or mean (SD)
Participant characteristics
Gender (number of men) 10 (71%) 11 (73%)
Age (years) 66.5 (2.1) 65.4 (3.0)
BMI (kg/m2) 30.9 (6.9) 32.5 (5.8)
Ethnicity
Caucasian 14 (100%) 15 (100%)
CCS Classiﬁcation
Class III 9 (64.3%) 9 (60%)
Class IV 5 (35.7%) 6 (40%)
BMI, body mass index; CCS, Canadian Cardiovascular Society functional
classiﬁcation of angina; SCS, spinal cord stimulation; UC, usual care.
Table 2. Patient Satisfaction at Six-Month Follow-Up.
SCS group UC group
N median (range) N median (range)
Satisﬁed with the pain relief *? 13 4 (2 to 4) 14 3 (2 to 4)
Based on experience so far,
would you have agreed
to this treatment†?
13 4 (2 to 4) 14 3 (2 to 4)
How acceptable was each
treatment‡?
Education session with
consultant
12 4 (3 to 4) 13 4 (3 to 4)
TENS machine 8 2 (1 to 4) 12 3 (1 to 4)
Thoracic sympathectomy 1 1 (1 to 1) 4 3.5 (2 to 4)
Medications 11 3 (1 to 4) 14 3 (2 to 4)
*4: very satisﬁed; 3: satisﬁed; 2: not satisﬁed; 1: very unsatisﬁed.†4: deﬁ-
nitely yes; 3: yes; 2: no; 1: deﬁnitely no.‡4: extremely acceptable; 3: accept-
able; 2: not acceptable; 1: extremely unacceptable.SCS, spinal cord
stimulation; TENS, transcutaneous electrical nerve stimulation; UC, usual
care.
Table 3. Primary and Secondary Outcome Scores at Baseline and Follow-Up.
Baseline Three-month follow-up Six-month follow-up
SCS group UC group SCS group UC group SCS-UC diﬀerence* SCS group UC group SCS-UC diﬀerence*
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD) Mean (95% CI) N Mean (SD) N Mean (SD) Mean (95% CI)
Primary outcome
Seattle Angina Questionnaire
Physical limitations 15 33.3 (15.4) 14 32.1 (15.3) 14 41.1 (18.6) 13 33.9 (15.8) −7.3 (−21.5 to 6.7) 14 38.5 (19.4) 14 33.9 (15.8) −3.5 (−14.6 to 7.7)
Angina stability 15 36.7 (18.5) 14 26.8 (6.7) 14 44.6 (20.0) 14 32.1 (15.3) −8.2 (−23.7 to 7.2) 13 46.2 (26.9) 14 37.5 (19.0) 0.5 (−16.9 to 17.9)
Angina frequency 15 29.3 (12.8) 14 27.1 (12.7) 14 32.8 (23.2) 14 32.8 (16.8) −17.8 (−33.1 to −2.5) 13 46.2 (26.3) 14 31.4 (21.7) −12.8 (−29.1 to 3.5)
Treatment status 15 80.0 (23.5) 14 73.2 (20.7) 14 85.7 (18.9) 14 83.9 (18.6) 4.1 (−9.3 to 17.5) 13 90.4 (16.2) 13 76.9 (21.6) −9.1 (−24.6 to 6.3)
Quality of life 15 36.7 (16.0) 14 30.4 (10.6) 14 55.4 (20.0) 14 35.7 (16.1) −19 (−32.6 to −5.3) 13 63.5 (21.9) 14 42.8 (22.8) −22.3 (−39.2 to −5.3)
Secondary outcomes
Frequency of angina attacks (per week) 15 22.0 (17.1) 14 14.6 (13.6) 12 11.2 (18.1) 14 16.1 (15.1) −8 (−22 to 6)
Rate ratio: 0.48
(0.37 to 0.62)
13 13.1 (19.8) 14 19.5 (20.9) −11 (−27 to 5)
Rate ratio: 0.41
(0.33 to 0.52)
Exercise capacity
Six-minute walking distance (m) 13 121 (98) 12 175 (100) Not assessed Not assessed — 10 191 (81) 9 140 (78) 60 (−4 to 123)
EQ-5D tariﬀ 15 0.27 (0.34) 14 0.50 (0.26) 14 0.53 (0.24) 14 0.52 (0.22) −0.1 (−0.3 to 0.1) 13 0.55 (0.29) 14 0.48 (0.24) −0.2 (−0.4 to 0)
Short-Form 36
Physical functioning 15 26.7 (23.4) 14 22.5 (17.4) 14 32.5 (16.9) 14 25.0 (21.6) 4.5 (−7.9 to 16.8) 13 31.1 (20.2) 14 28.6 (28.0) 0.1 (−18.8 to 18.9)
Role limitations caused by physical
problems
15 3.3 (8.8) 14 1.8 (6.7) 14 16.1 (23.2) 14 5.4 (14.5) 10.6 (−5.8 to 27.1) 13 13.4 (21.9) 14 5.4 (10.6) 5.9 (−6.4 to 18.2)
Role limitations caused by emotional
problems
15 33.3 (43.6) 14 33.3 (43.6) 14 69.0 (46.2) 14 47.6 (42.8) 26.6 (−.6.6 to 59.4) 13 71.7 (40.5) 14 40.4 (47.2) 28.8 (−2.6 to 60.3)
Energy/vitality 15 28.7 (21.2) 14 27.5 (17.6) 13 38.8 (16.1) 14 26.8 (15.9) 9.6 (−1.5 to 20.7) 13 38.8 (18.5) 14 26.8 (18.5) 16.4 (4.6 to 28.2)
Mental health 15 53.3 (23.5) 14 58.8 (19.7) 13 67.1 (23.4) 14 62.3 (20.9) 8.5 (−5.2 to 22.2) 13 72.6 (16.6) 14 63.7 (17.8) 11.5 (1.3 to 21.7)
Social functioning 15 30.8 (24.5) 14 41.1 (13.4) 15 49.1 (34.8) 14 45.5 (18.7) 6.8 (−11.4 to 25.1) 13 52.9 (24.6) 14 47.3 (23.1) 9.8 (−7.1 to 26.6)
Bodily pain 15 22.2 (14.5) 14 29.6 (10.4) 13 36.9 (18.3) 14 35.4 (17.7) 4.0 (−11.6 to 19.6) 13 42.3 (16.9) 14 35.4 (11.3) 8.8 (−3.7 to 21.4)
General health 15 56.0 (10.6) 14 53.2 (8.4) 13 57.7 (11.6) 14 50.7 (9.2) 3.3 (−5.1 to 11.7) 13 54.2 (7.9) 14 52.1 (12.0) −0.1 (−7.4 to 7.2)
*Between-group diﬀerence adjusted for baseline score and stratiﬁcation variables (i.e., center, CCS class, age <65 vs. ≥65 years.CCS, Canadian Cardiovascular
Society functional classiﬁcation of angina; SCS, spinal cord stimulation; UC, usual care.4
ELDABE ET AL.
www.neuromodulationjournal.com Neuromodulation 2015; ••: ••–••© 2015 The Authors. Neuromodulation: Technology at the Neural Interface
published by Wiley Periodicals, Inc. on behalf of International Neuromodulation Society
treatments received by participants in either SCS or UC groups over
the period of study. However, UC treatments received by both
groups were documented.
Outcome Measures
We collected the following pilot study outcomes:
1. Recruitment and retention: We documented procedures for
recruiting patients in both groups and any problems that have
arisen during this process. Retentionwas assessed by document-
ing the number of dropouts and lost to follow-up in both groups.
2. Feasibility and acceptability of design:We quantiﬁed the time for
attainment of recruitment numbers against preplanned targets,
the proportion of suitable patients who failed to provide
consent, and the ratio of participants screened vs. randomized.
3. Feasibility and acceptability of treatment: Patients were asked
to assess their willingness to recommend SCS or UC to other
patients. This was assessed by three questions based on a Likert
response scale: Are you satisﬁed with the pain relief provided
by your treatment? Very Satisﬁed/Satisﬁed/Unsatisﬁed/Very
Unsatisﬁed; Based on your experience so far, would you have
agreed to this treatment? Deﬁnitely Yes/Yes/No/Deﬁnitely No;
Can you tell us how acceptable these treatments were to you?
[list of treatments provided] Extremely acceptable/Acceptable/
Not acceptable/Extremely unacceptable /Not Applicable.
4. Feasibility and acceptability of proposed patient outcome mea-
sures: quantiﬁed as the number of returned and complete
outcome assessments available for assessment.
5. Outcome variance: Mean and standard deviation for all out-
comes were calculated for each group at all assessment visits (to
inform power calculations for a deﬁnitive trial).
Patient outcome measures were collected at baseline
(prerandomization), and three and six months postrandomization
by a clinic visit undertaken by the research nurse. The study’s
primary outcome parameter was disease-speciﬁc HRQoL assessed
using the UK version of the Seattle Angina Questionnaire (SAQ) (26).
The SAQ quantiﬁes patients’ physical limitations caused by angina,
the frequency of and recent changes in their symptoms, their satis-
faction with treatment, and the degree to which they perceive their
disease to aﬀect their quality of life. Each scale is transformed to a
score of 0 to 100, where higher scores indicate better function (e.g.,
less physical limitation, less angina, and better quality of life). Sec-
ondary outcomes included: angina attacks recorded by diary for a
week; exercise capacity assessed by a symptom-limited treadmill;
and generic HRQoL assessed using the EuroQol (EQ-5D-3L) con-
verted into single (utility) indices using the UK tariﬀ (27) and Short
Form-36 (SF-36) questionnaires (28,29). Exercise capacity was
assessed at baseline and six months follow-up only. Where patients
were unable or unwilling to undertake a symptom-limited treadmill
test, a six-minute walk test was instead undertaken. To allow com-
parison over time, each participant performed the same exercise
tests at baseline and follow-up. The nature and frequency of device-
speciﬁc and nondevice complications and adverse events (serious
and nonserious) were collected for both groups at each follow-up
visit and in-between visits.
Statistical Analysis
Study sample size was chosen to inform the feasibility objectives
of this study, i.e., provide suﬃciently precise estimates of the likely
rates of recruitment and retention, and to yield estimates of the
variability of the primary and secondary outcomes to inform power
calculations for a subsequent full-scale RCT. We sought to recruit
and randomize a total of 45 RA patients (15 per center) over a
20-month period.
Given the pilot nature of this trial, we did not seek to formally
inferentially test and report p values for the comparison of out-
comes either between or within SCS and UC groups. Instead, we
report mean and standard deviation (or relevant summary
statistics) for both groups for all assessments at each follow-up
Figure 2. Between-groupmean diﬀerence at three and sixmonths for angina frequency (SAQ) adjusted for baseline score and stratiﬁcation variables (i.e., center, CCS
class, age <65 vs. ≥65 years). Error bars represent standard error of diﬀerence. Positive between-group diﬀerence in SAQ indicates superior scores for SCS group
compared with UC group. CCS, Canadian Cardiovascular Society functional classiﬁcation of angina; SAC, Seattle Angina Questionnaire; SCS, spinal cord stimulation;
UC, usual care.
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point based on the intention-to-treat principle (i.e., according to
the original randomization). We also report the mean (and 95%
CIs) between group diﬀerence in outcomes at three- and six-
month follow-up adjusting for baseline outcome score and strati-
ﬁcation variables. The between-group diﬀerence in angina
frequency is also reported as a rate ratio. All analyses were con-
ducted using STATA (Release 13.1; College Station, TX, USA:
StataCorp LP).
RESULTS
Recruitment, Retention, and Feasibility of Design
Study enrollment, allocation to the SCS and UC groups, and
follow-up of study participants are summarized in the CONSORT
ﬂow diagram shown in Figure 1. Sixty-seven patients were screened
and a total of 29 RA patients were randomized (SCS group: 15; UC
group: 14), a screening to randomization ratio of 2.3:1. The original
forecast was a recruitment rate of 1.5 patients per month. However,
the actual recruitment rate across the initial three sites was 0.7
patients per month. Given this lower recruitment rate, the period of
recruitment had to extend by 22months and took place over a total
of 42 months (January 2011 to June 2014) and a fourth center was
opened (on month 24).
None of the patients recruited into the study declined his/her
treatment allocation and none of the referring physicians counseled
patients against their treatment allocation. No participants chose to
withdraw from the study. No patients required repeat angiography
during the study period.
Baseline Characteristics and Assessments
There appeared to be good balance between SCS and UC group
participants in terms of their baseline demographic characteristics
(Table 1). However, there was evidence of imbalance in some of the
primary and secondary assessment scores as summarized inTable 1.
Other cardiovascular morbidities included hypercholesterolemia
(N = 23), family history of coronary artery disease (N = 22), hyper-
tension (N = 19), insulin-dependent diabetes mellitus (N = 5), body
mass index > 30 (N = 14), and smoking (current smoker N = 3;
previous smoker N = 19). Previous treatments include coronary
artery bypass graft (N = 24), TENS (N = 7), stents (N = 14), percuta-
neous coronary intervention (N = 6), stellate ganglion blocks (N = 3),
and anti-anginamedications (N = 29). Seventy-six percent (22/29) of
the patients were taking eight or more diﬀerent cardiovascular
medications, including anticoagulants, antiplatelets, beta blockers,
ACE-inhibitors or angiotensin receptor blockers, aldosterone
antagonists, and the full range of available antianginal agents.
Acceptability of Treatment Received
Participants in both SCS and UC groups generally rated their
acceptability with treatment as good (Table 2). The number of
patients receiving UC therapies was equal to the number of
responders to the patient’s satisfaction/acceptability question-
naire. In the SCS group, one patient received thoracic sympathec-
tomy after randomization but before SCS implantation. Eight
patients used TENS following randomization and until the SCS
implantation. Patients in the SCS group did not use TENS following
SCS implant. Median satisfaction with pain relief and agreement to
receipt of treatment were 4 (i.e., rating of “very satisﬁed” and “deﬁ-
nitely yes,” respectively) in the SCS group and 3 (i.e. rating of “sat-
isﬁed” and “yes”) in the UC group. There was some evidence of
higher scores for SCS than UC. Acceptability of speciﬁc UC thera-
pies was variable.
Feasibility of Outcome Collection and Outcome Results at
Follow-Up
Primary and secondary outcomemeasures were completed by all
29 randomized patients at baseline. Allowing for two deaths,
Figure 3. Between-group mean diﬀerence at three and six months for frequency of angina attacks adjusted for baseline score and stratiﬁcation variables (i.e.,
center, CCS class, age <65 vs. ≥65 years). Error bars represent standard error of diﬀerence. Negative between-group diﬀerence indicates larger reduction in
angina frequency in SCS group compared with UC group. CCS, Canadian Cardiovascular Society functional classiﬁcation of angina; SCS, spinal cord stimulation; UC,
usual care.
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outcomes were completed at three and six-month follow-up in the
27 remaining participants.While the vastmajority of patients under-
took the six-minute walk test, only two patients were able to
perform a symptom-limited treadmill test. Primary and secondary
outcome results at three months and six months follow-up are
shown in Table 3. There was a consistent pattern of a positive
change in both SCS and UC groups in outcomes at three- and six-
month follow-up compared to baseline, i.e., increases in SAQ scores,
exercise capacity, EQ-5D tariﬀ, and SF-36 scores, and a reduction in
the frequency of angina attacks. The magnitude of these outcome
improvements appeared to be higher for the SCS than the UC group
(Figs. 2–6).
Adverse Events
Two participants died of causes related to their RA (i.e., cardio-
genic shock and cardiac arrest) but were judged to be unrelated to
study procedures. Both were randomized to the SCS group; one
receiving a permanent implant and the other failing the SCS screen-
ing trial.
A total of 25 adverse events were recorded over the six-month
study follow-up (see Table 4). Of these, four were related to SCS
therapy: two cases of superﬁcial infection, one case of pain over
the implant, and one case of inadequate paresthesia coverage.
Five adverse events were related to antiangina therapy and
included three cases of headache, one case of diplopia, and one
Figure 4. Between-group mean diﬀerence at three and six months for SAQ angina quality of life score adjusted for baseline score and stratiﬁcation variables (i.e.,
center, CCS class, age <65 vs. ≥65 years). Error bars represent standard error of diﬀerence. Positive between-group diﬀerence in SAQ indicates superior scores for SCS
group compared with UC group. CCS, Canadian Cardiovascular Society functional classiﬁcation of angina; SAC, Seattle Angina Questionnaire; SCS, spinal cord
stimulation; UC, usual care.
Figure 5. Between-group mean diﬀerence at three and six months for EQ-5D tariﬀ adjusted for baseline score and stratiﬁcation variables (i.e., center, CCS class, age
<65 vs. ≥65 years). Error bars represent standard error of diﬀerence. Positive between-group diﬀerence in EQ-5D tariﬀ indicates superior scores for SCS group
compared with UC group. CCS, Canadian Cardiovascular Society functional classiﬁcation of angina; SCS, spinal cord stimulation; UC, usual care.
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case of dizziness. Twelve participants required hospitalization (six
SCS group, six UC group), ﬁve for the treatment of chest pain, one
for intravenous antibiotic treatment of SCS-related infection. Five
admissions were unrelated to angina or study procedures
(hemiplegic migraine and epilepsy, vestibular pathology, pulmo-
nary edema and septic shock, migraine, cellulitis left leg). The
patient admitted with pulmonary edema and septic shock made a
full recovery.
DISCUSSION
A pilot study was undertaken to inform progression to a
fully powered randomized trial to determine the clinical eﬀective-
ness and cost-eﬀectiveness of the addition of SCS to UC compared
with UC alone in patients with RA. Patient recruitment was
found to be challenging in this pilot; we failed to achieve the
target study sample size, recruiting and randomizing 29 patients
out of the original target of 45. Nevertheless, once patients were
randomized, we found participant retention and outcome comple-
tion to be very high; except for two patients who died due to
their disease during the study, there was no loss to follow-up and
all participants provided outcomes at three- and six-month
follow-up.
Although not formally powered to compare outcomes either
within or between groups, we did see evidence of an improvement
in HRQoL demonstrated by the disease-speciﬁc SAQ as well as
generic quality of life questionnaires, exercise capacity, and reduc-
tion in angina frequency at follow-up in both the SCS and UC
groups, with a trend towards larger improvements in the SCS group.
Figure 6. Exercise capacity at six months for SCS and UC group and between-groupmean diﬀerence for six-minute walking distance adjusted for baseline score and
stratiﬁcation variables (i.e., center, CCS class, age <65 vs. ≥65 years). Error bars represent standard error of diﬀerence. Positive between-group diﬀerence in six-minute
walking distance indicates superior scores for SCS group comparedwith UC group. CCS, Canadian Cardiovascular Society functional classiﬁcation of angina; SCS, spinal
cord stimulation; UC, usual care.
Table 4. Serious Adverse Events Observed During the Study Period.
Site Randomized to: Serious adverse event Category Device related
01 UC Hemiplegic migraine and epilepsy Hospitalization No
UC Central chest pain (unstable angina) Hospitalization No
UC Migraine and nonepileptic seizures, right occipital nerve neuralgia and chest pain Hospitalization No
SCS Ongoing microvascular angina Hospitalization No
02 SCS Exacerbation of angina—unrelieved by GTN spray Hospitalization No
SCS Cardiogenic shock Death No
03 UC Chest pains Hospitalization No
UC Chest pains Hospitalization No
SCS Cardiac arrest Death No
SCS Vestibular pathology Hospitalization No
SCS SCS infection Hospitalization Yes
UC Pulmonary edema and septic shock Hospitalization No
SCS Migraine Hospitalization No
SCS Cellulitis left hand Hospitalization No
04 No SAEs reported
GTN, glyceryl trinitrate; SAE, serious adverse event; SCS, spinal cord stimulation; UC, usual care.8
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This trend can be partly explained by baseline diﬀerences and
without a sham comparator we cannot rule out the possibility of a
placebo eﬀect contributing to improvements with SCS. In addition,
SCS appeared to be a safe therapy in RA; there was one device-
related serious adverse event over the six-month follow-up period
of the trial. One patient randomized to SCS had a failed test trial, a
success rate of 93%. These ﬁndings are in agreement with those of
previous clinical studies and systematic reviews of SCS in RA
(18,19,30–32). RA is a condition aﬀecting an elderly population with
numerous comorbidities. We did not ﬁnd this to be a barrier to SCS
implant or usage in this population.
The main strengths of this study were its randomized trial design
and the ability to retain patients once recruited. However, the pilot
did have limitations. Although study logs recorded 67 patients to be
screened, it was apparent from discussions with the study sites that
many more patients were deemed to not fulﬁll the study entry
criteria from the referral letter such as: no clear demonstrable isch-
emia, severe spinal pain, and the presence of other implanted
devices. Slowpatient recruitment, resulting in study termination, has
beenpreviously reported inanevaluationof SCS forRA;however, the
possible reasons for slow recruitment were not discussed (32).
Causes for the slow recruitment in our study include higher than
expected screening failures; the majority of screening failures were
subjects referred with symptoms typical of RA but no demonstrable
reversible ischemia on functional testing. The requirement to dem-
onstrate reversible ischemia on functional testingwas agreed by the
study steering committee at its initial meeting to be important to
provide a homogenous population suﬀering from chest pain related
to ischemia rather than other potential causes such as atypical and
functional chest pain. We believe that this single inclusion criterion
had the most profound eﬀect on our ability to recruit to this study.
The requirement for demonstration of ischemia as the etiology of RA
is explicit in the deﬁnition of RA coined by the European Task Force
(33). By contrast, the UK RA group deﬁned the condition as chronic
stable angina that persists despite optimal medication and when
revascularization is unfeasible or where the risks are unjustiﬁed (34).
It has been recently proposed that the deﬁnition of RA should be
more precise by specifying the reason for revascularization unsuit-
ability, such as microvascular dysfunction, epicardial stenosis, or
generalized lesions (35). Finally, the study encountered protracted
negotiations with the Primary Care Trusts relating to excess treat-
ment costs (ETC) associatedwith the devices and the implant proce-
dure, which resulted in signiﬁcant delays.
Implications for Planning a Future Trial
The study demonstrates the importance of a pilot and feasibility
research prior to conducting a fully funded powered RCT (36). The
key ﬁnding from the pilot trial is the need for a multifaceted
approach to ensure the recruitment of patients in order to meet the
needs of a future deﬁnitive trial. Based on a minimally important
diﬀerence of 10 (37) on the SAQ and the conservative estimates of
both standard deviation of 20 and attrition rate of 20% (except for
two deaths, we saw no loss to follow-up in this pilot), a deﬁnitive
trial will need to recruit 110 patients per group at 90% power and
5% alpha. Future studies exploring SCS use in RAmay wish to adopt
the UK group deﬁnition, which does not stipulate the demonstra-
tion of reversible ischemia as a cause for the angina but takes amore
patient-centered view of the condition. We observed a variation in
the point of diagnosing RA between the sites. The deﬁnition of RA
was seen to diﬀer in some centers where some of the research sites
required an attempt of all potential medication choices before diag-
nosing patients as suﬀering from RA and referring to the study.
Recruitment rates may be increased with greater education regard-
ing the treatment options for these patients and the involvement of
general practitioners and patient groups. SCS implantation by car-
diologists should also be considered. We however would like to
point out that we have during the recruitment period of this study
contacted GP practices and invited them to refer patients with no
success. A number of elderly subjects required some assistance with
outcomemeasure completion from the study nurse. The six-minute
walk test was more acceptable to an RA population than the tread-
mill test. A future trial should include use of the six-minute walk test
in preference to the treadmill as well as provision of a study-
independent professional to conduct exercise tests in a blinded
manner. The patients randomized to UC considered the treatment
options available to be acceptable and based on their experience
would have agreed to receive these treatments. Subgroup analysis
should include analysis of patients allocated to the SCS group with
respect to prior treatments with therapies aﬀecting the nervous
system, such as TENS, stellate ganglion blockade, or sympathec-
tomy vs. naive patients. We conclude that the study outcome mea-
sures are acceptable and appropriate for a future RCT. Collection of
some of the interim data by post with telephone guidance where
required should be considered by a future RCT. This will reduce
the patient burden in an elderly population with multiple
comorbidities.
CONCLUSION
In summary, there were several diﬃculties associated with
recruitment of patients for this study, including a higher than
expected screening failure, diﬃculty in conﬁrming whether indi-
vidual patients met the entry criteria of reversible ischemia, a lack of
consensus on the point at which a diagnosis of RA is reached, and
protracted negotiations with local hospitals and primary care trusts
relating to agreement of device and procedure costs for the trial. By
contrast, we managed to retain and collect three- and six-month
outcomes from all surviving participants.We found SCS therapy and
trial outcomemeasures to be acceptable and appropriate for future
RCTs. Althoughwewere not formally powered to investigatewithin-
or between-group treatment diﬀerences, compared with baseline,
there were trends across a number of the outcomes (including exer-
cise capacity and HRQoL) of larger improvements in the SCS com-
pared with UC group at three and six months. In addition, SCS
appeared to be a safe therapy; there was one device-related serious
adverse event over the six-month follow-up period of the trial.
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